Interleukin-2 liposomal - Therapeutics 2000

Drug Profile

Interleukin-2 liposomal - Therapeutics 2000

Latest Information Update: 22 Aug 2002

Price : $50

At a glance

  • Originator Therapeutics 2000
  • Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Lung cancer

Most Recent Events

  • 02 Nov 1998 Preclinical development for Lung cancer in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top